How to use the speech recognition tool?
Rate of Progression in USH2A Related Retinal Degeneration.
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: NA
- Opening Date: 2017-08-01
- Closing Date: 2021-12-31
Inclusion: Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years
Exclusion: Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History
Funder Type: patient organisation
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by: